company background image
TMO

Thermo Fisher ScientificNYSE:TMO Stock Report

Market Cap

US$238.7b

7D

8.5%

1Y

45.5%

Updated

23 Sep, 2021

Data

Company Financials +
TMO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance6/6
Financial Health4/6
Dividends0/6

TMO Overview

Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide.

Thermo Fisher Scientific Competitors

Illumina

NasdaqGS:ILMN

US$63.8b

Agilent Technologies

NYSE:A

US$52.2b

Waters

NYSE:WAT

US$24.3b

Bio-Rad Laboratories

NYSE:BIO

US$23.4b

Price History & Performance

Summary of all time highs, changes and price drops for Thermo Fisher Scientific
Historical stock prices
Current Share PriceUS$608.23
52 Week HighUS$412.80
52 Week LowUS$614.13
Beta0.75
1 Month Change10.49%
3 Month Change23.41%
1 Year Change45.46%
3 Year Change148.95%
5 Year Change289.74%
Change since IPO6,602.94%

Recent News & Updates

Shareholder Returns

TMOUS Life SciencesUS Market
7D8.5%3.2%-0.5%
1Y45.5%59.6%37.5%

Return vs Industry: TMO underperformed the US Life Sciences industry which returned 58.3% over the past year.

Return vs Market: TMO exceeded the US Market which returned 36.2% over the past year.

Price Volatility

Is TMO's price volatile compared to industry and market?
TMO volatility
TMO Beta0.75
Industry Beta0.97
Market Beta1

Stable Share Price: TMO is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: TMO's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
195680,000Marc Casperhttps://www.thermofisher.com

Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories.

Thermo Fisher Scientific Fundamentals Summary

How do Thermo Fisher Scientific's earnings and revenue compare to its market cap?
TMO fundamental statistics
Market CapUS$238.66b
Earnings (TTM)US$8.60b
Revenue (TTM)US$38.25b

27.8x

P/E Ratio

6.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TMO income statement (TTM)
RevenueUS$38.25b
Cost of RevenueUS$18.62b
Gross ProfitUS$19.63b
ExpensesUS$11.04b
EarningsUS$8.60b

Last Reported Earnings

Jul 03, 2021

Next Earnings Date

n/a

Earnings per share (EPS)21.76
Gross Margin51.33%
Net Profit Margin22.47%
Debt/Equity Ratio51.0%

How did TMO perform over the long term?

See historical performance and comparison

Dividends

0.2%

Current Dividend Yield

4%

Payout Ratio

Valuation

Is Thermo Fisher Scientific undervalued compared to its fair value and its price relative to the market?

27.84x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: TMO ($608.23) is trading above our estimate of fair value ($390.86)

Significantly Below Fair Value: TMO is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: TMO is good value based on its PE Ratio (27.8x) compared to the US Life Sciences industry average (52.2x).

PE vs Market: TMO is poor value based on its PE Ratio (27.8x) compared to the US market (17.7x).


Price to Earnings Growth Ratio

PEG Ratio: TMO is poor value based on its PEG Ratio (14.9x)


Price to Book Ratio

PB vs Industry: TMO is overvalued based on its PB Ratio (6.5x) compared to the US Life Sciences industry average (6.1x).


Future Growth

How is Thermo Fisher Scientific forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

1.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TMO's forecast earnings growth (1.9% per year) is below the savings rate (2%).

Earnings vs Market: TMO's earnings (1.9% per year) are forecast to grow slower than the US market (14.9% per year).

High Growth Earnings: TMO's earnings are forecast to grow, but not significantly.

Revenue vs Market: TMO's revenue (7.9% per year) is forecast to grow slower than the US market (9.8% per year).

High Growth Revenue: TMO's revenue (7.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TMO's Return on Equity is forecast to be high in 3 years time (29.7%)


Past Performance

How has Thermo Fisher Scientific performed over the past 5 years?

29.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TMO has high quality earnings.

Growing Profit Margin: TMO's current net profit margins (22.5%) are higher than last year (14.3%).


Past Earnings Growth Analysis

Earnings Trend: TMO's earnings have grown significantly by 29.6% per year over the past 5 years.

Accelerating Growth: TMO's earnings growth over the past year (127.2%) exceeds its 5-year average (29.6% per year).

Earnings vs Industry: TMO earnings growth over the past year (127.2%) exceeded the Life Sciences industry 56.9%.


Return on Equity

High ROE: TMO's Return on Equity (23.3%) is considered high.


Financial Health

How is Thermo Fisher Scientific's financial position?


Financial Position Analysis

Short Term Liabilities: TMO's short term assets ($19.3B) exceed its short term liabilities ($6.9B).

Long Term Liabilities: TMO's short term assets ($19.3B) do not cover its long term liabilities ($23.9B).


Debt to Equity History and Analysis

Debt Level: TMO's debt to equity ratio (51%) is considered high.

Reducing Debt: TMO's debt to equity ratio has reduced from 67% to 51% over the past 5 years.

Debt Coverage: TMO's debt is well covered by operating cash flow (54.6%).

Interest Coverage: TMO's interest payments on its debt are well covered by EBIT (22.8x coverage).


Balance Sheet


Dividend

What is Thermo Fisher Scientific current dividend yield, its reliability and sustainability?

0.17%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: TMO's dividend (0.17%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.35%).

High Dividend: TMO's dividend (0.17%) is low compared to the top 25% of dividend payers in the US market (3.63%).


Stability and Growth of Payments

Stable Dividend: TMO is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: TMO is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: TMO is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TMO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average management tenure


CEO

Marc Casper (53 yo)

11.92yrs

Tenure

US$26,390,073

Compensation

Mr. Marc N. Casper has been the Chief Executive Officer and President of Thermo Fisher Scientific, Inc. since October 15, 2009 and also has been its Chairman of the Board of Directors since February 26, 20...


CEO Compensation Analysis

Compensation vs Market: Marc's total compensation ($USD26.39M) is above average for companies of similar size in the US market ($USD11.36M).

Compensation vs Earnings: Marc's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: TMO's management team is considered experienced (3.7 years average tenure).


Board Members

Experienced Board: TMO's board of directors are considered experienced (9.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TMO insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Thermo Fisher Scientific Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Thermo Fisher Scientific Inc.
  • Ticker: TMO
  • Exchange: NYSE
  • Founded: 1956
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$238.660b
  • Shares outstanding: 393.42m
  • Website: https://www.thermofisher.com

Number of Employees


Location

  • Thermo Fisher Scientific Inc.
  • 168 Third Avenue
  • Waltham
  • Massachusetts
  • 2451
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/23 22:54
End of Day Share Price2021/09/23 00:00
Earnings2021/07/03
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.